Skip to content
Peptigraph home

Cagrilintide

Amylin analog. Cagrilintide is investigational and not approved for any use.

Also called:cagricag
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT evidence, 4 of 4
StatusInvestigational (CagriSema component)Prohibited by WADA (S0)Full legal history

Key facts

Class
Amylin analog
Also called
cagri, cag
Vial sizes sold
2.5 mg, 5 mg, 10 mg
Community-reported sizes
Half-life
159-195 h (with semaglutide 2.4 mg co-administered)
subcutaneous, in people · Lancet 2021, PMID 33894838
FDA status
Not approved
Investigational (CagriSema component)
WADA
Prohibited (S0)
In and out of competition
Everything on Cagrilintide

Cagrilintide guides

Vial and dose sizes

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

Cagrilintide: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Weight lossNot in our ledgerNot in our ledger4Human RCT evidence, 4 of 4Lancet 2021, PMID 34798060
Heart healthNot in our ledgerNot in our ledger2Human RCT evidence, 4 of 4Diabetes, obesity & metabolism 2024, PMID 39279639

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

An amylin analogue, not a GLP-1 drug

Cagrilintide (code name AM833) is a lipidated amylin analog described as a nonselective agonist of amylin and calcitonin receptors, not of the GLP-1 receptor.[8]

A mouse study found its weight-lowering effect depends on the AMY1R and AMY3R amylin receptors in the brain.[9]

What was found alone, and what only in combination

The phase 2 obesity trial found mean weight reductions of 6.0%-10.8% across cagrilintide doses, versus 3.0% on placebo.[4]

At 4.5 mg it beat liraglutide 3.0 mg, 10.8% against 9.0% weight reduction, an estimated difference of 1.8%.[4]

A meta-analysis found that cagrilintide alone lowered weight and blood pressure without meaningful HbA1c improvement.[10]

Safety checks that exist

A thorough QT study in healthy volunteers found no clinically relevant QT prolongation at the last 4.5-mg dose.[7]

Single-dose kidney and liver impairment studies found exposure similar across groups.[5]

Regulatory path

Drugs@FDA has no entry for cagrilintide.[2]

Cagrilintide is not named on the WADA list; as an investigational drug without approval it falls under the S0 catch-all.[1]

Compared with

Common stacks

Cagrilintide is often sold pre-mixed or combined with other peptides. A few of these pairs appear together in published studies; each stack page lists what was tested, and the pages below cover the math and what each part has been studied for.

Common questions

Is Cagrilintide FDA approved?

No. Cagrilintide is investigational (investigational (cagrisema component)) and not approved for any use.

Is Cagrilintide banned in sport?

Yes. Prohibited by WADA (S0), so it is prohibited at all times for tested athletes.

How much water goes in a 10 mg vial?

That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.

What is cagrilintide?

An investigational long-acting analogue of the hormone amylin.[8]

What does cagrilintide do?

In a phase 2 trial it produced weight reductions of 6.0%-10.8%; it is also tested with semaglutide as CagriSema.[4]

What is the half-life of cagrilintide?

In the combination phase 1b trial with semaglutide, cagrilintide had a half-life of 159-195 h.[6]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "cagrilintide" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  3. 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  4. 4Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.Lancet (London, England) · 2021PMID 34798060Accessed 2 Oct 2026
  5. 5Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clinical pharmacokinetics · 2026PMID 42228334Accessed 2 Oct 2026
  6. 6Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026
  7. 7Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.Diabetes, obesity & metabolism · 2024PMID 39279639Accessed 2 Oct 2026
  8. 8AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists.The Journal of pharmacology and experimental therapeutics · 2021PMID 33727283Accessed 2 Oct 2026
  9. 9Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.EBioMedicine · 2025PMID 40609154Accessed 2 Oct 2026
  10. 10Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.Annals of medicine and surgery (2012) · 2026PMID 42583410Accessed 2 Oct 2026

Found an error? Report a correction.